HONG KONG, Oct. 7 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ("CCBC" or "the Company") (NYSE: CO), the first and largest cord blood bank operator in China, today announced that since the authorization of the stock repurchase program on September 15, 2010, the Company has repurchased approximately 309,000 ordinary shares for approximately US$1.6 million through October 6, 2010 at an average price per share of US$5.32. This amount represents approximately 10.7% of the total repurchase program authorized by CCBC's Board of Directors, with approximately US$13.4 million remaining in the Company's buyback authorization for repurchase prior to September 2011.

Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation, stated, "We are committed to enhancing shareholder value, and our actions in the past weeks demonstrate our commitment to our shareholders and management's confidence in the Company's business and future prospects. We do not believe the current share price reflects the intrinsic value of the Company's business. Our expansion plan in Zhejiang province that was announced in September, together with our intention to execute the warrant exchange offer to simplify our capital structure, should contribute to a stronger earnings profile. We plan to continue to grow our existing business, and at the same time, seek opportunities to expand our business in China and the Asia Pacific region."

About China Cord Blood CorporationChina Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. '/>"/>

(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Gene Therapy - ... , Gene therapy technologies are ... and cell therapy with genetically modified vectors. Gene ... and various routes of administration as well as ...

(Date:3/3/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announced it has initiated commissioning activities for its 30,000 ... Sarnia, Ontario , Canada. Commissioning ... with the facility being in commercial operation in Q3 ... two months and it is carrying out commissioning and ...

... March 25, 2011 BioNeutral Group, Inc. (OTC Bulletin ... technology-based company, today announced the appointment of Dr. Stephen ... and a medical practitioner in New York State, as ... Director. Dr. Holt is an independent consultant to the ...

(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...

(Date:1/22/2015)... OXFORD, Conn. , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: ... growing mobile commerce market, reports on the recent success of the Wocket™ ... Wocket smart wallet was named as one of the ... of the "5 Best Products Launched At CES So Far" by Newseveryday.com ...

... of microbiologists led by Indiana University researchers has identified a ... single end or pole of the cell instead of uniform, ... that could have implications in the development of new antibacterial ... bacteria such as Escherichia coli and Bacillus ...

Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...